Get Involved
On the day

FDA awards Novartis expanded approval for breast cancer therapy

Posted:

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers. 

Read the full article here.

Previous post
Back to list
Next post